# US 2024/0197715 A1 · Pharmaceutical combinations and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197715 A1
- Document ID: US20240197715A1
- Status: Published application
- Kind: A1
- Application number: 18/510,836
- Filed: 2023-11-16
- Published: 2024-06-20
- Earliest claimed: 2022-11-18
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Rita ANDRAOS-REY; Sandra BLUM-KALLERT; Marta CORTES-CROS; Ruben DE KANTER; Stephane FERRETTI; Isabel Cristina Colaco Farias JACO; Jacques HAMON; Jürgen Hans-Hermann HINRICHS; Laurent LABORDE; Henrik MOEBITZ; Michele MOSCHETTA; Joseph SCHOEPFER; Ross Sinclair STRANG
- Web page: https://patentgrep.com/patent/US20240197715A1

## CPC

- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/52: Purines, e.g. adenine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a pharmaceutical combination comprising a WRN inhibitor in combination with at least one additional therapeutically active agent. It also provides a method of treating cancer, involving administering to a subject in need thereof the WRN inhibitor in combination with the at least one additional therapeutically active agent. For example, the WRN inhibitor compound, or a pharmaceutically acceptable salt thereof, is of formula (I): wherein R1, R2, R3, R4, R5, R28, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein.

## Claims

### Claim 1

A WRN inhibitor for use in the treatment of cancer, wherein the treatment further comprises administration of:
i. an agent which can
sensitise the cancer cells, for example for an improved response to treatment with a WRN inhibitor,
prime the cancer cells, for example, such priming may include triggering hypermutation status in cancer cells,
create or increase MMR deficiency in cancer cells,
create or increase MSI-H status in cancer cells, or
increase MMR heterogeneity of cancer cells,
and optionally wherein the treatment further comprises administration of:
ii. a chemotherapy, for example irinotecan.

### Claim 2 (depends on 1)

A WRN inhibitor for use as claimed in claim 1, wherein the cancer is MSS (microsatellite stable) cancer.

### Claim 3 (depends on 1, 2)

A WRN inhibitor for use as claimed in claim 1 or claim 2, wherein the agent i. is selected from temozolomide, cisplatin and 6-thioguanine, or the agent i. is an ionising radiation based therapy selected from i) external beam radiation, ii) brachytherapy and ii) a radiopharmaceutical.

### Claim 4 (depends on 1, 2, 3)

A WRN inhibitor for use as claimed in any of claims 1 to 3, wherein the agent i. is temozolomide.

### Claim 5 (depends on 1, 2, 3, 4)

A WRN inhibitor for use as claimed in any of claims 1 to 4, wherein the treatment further comprises administration of i. temozolomide and ii. irinotecan.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A WRN inhibitor for use as claimed in any of claims 1 to 5, wherein the WRN inhibitor is a compound of formula (1g), or a pharmaceutically acceptable salt thereof:
wherein
R1 is selected from:
R15 is H or F;
R16 is H or R25(R24)N—;
R17 is H or F;
R18 is H or F;
R19 is H or F;
R20 is H or F;
R21 is H or CH3;
R22 is H, CF3, CHF2CH2, HOC(O)—CH2—, H3C—C(O)—, (H3C)3C—O—C(O)—;
R23 is H, CF3, CHF2CH2, (H3C)3C—O—C(O)—;
R24 is CH3;
R25 is CHF2CH2—;
R28 is CH3, H or deuterium;
R27 is H or deuterium;
R2 is the moiety:
wherein R6 is selected from H, Cl, CH3, F, and Br;
R8 is selected from H, Cl, F and CF3;
R9 is selected from H, CH3 and Cl;
R28 is selected from CF3, CF2H, —CH2CH3, Cl, SF5, Br and —C(O)H;
X is selected from C—R7 and N;
R7 is selected from H and F;
R3 is selected from CH3, CH2CH3, cyclopropyl and hydroxyethyl;
R4 is selected from:
wherein
R10 is selected from H, F, Cl, CH3 and OCF3;
R11 is selected from H, Cl, F, and CH3;
R12 is selected from H, Cl and CH3;
R13 is selected from H and CH3;
R14 is selected from H, CH3, —CH2CH3, cyclopropyl, —OCHF2, OCF3 and Cl;
y is 0, 1 or 2;
R5 is CH3; or alternatively, two R5 groups on adjacent carbon atoms join, along with the carbon atoms to which they are attached, to form a fused cyclobutyl ring:
and
* indicates a point of attachment.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A WRN inhibitor for use as claimed in any of claims 1 to 6, wherein the WRN inhibitor is Compound A:
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A WRN inhibitor for use as claimed in any of claims 1 to 7, wherein the cancer is selected from colorectal cancer (CRC), such as colon adenocarcinoma or rectal adenocarcinoma, gastric cancer, such as stomach adenocarcinoma, prostate cancer, endometrial cancer, adrenocortical cancer, such as adrenocortical carcinoma, cervical cancer, such as cervical squamous cell carcinoma or endocervical adenocarcinoma, uterine cancer, such as uterine corpus endometrial carcinoma and uterine carcinosarcoma, esophageal cancer, such as esophageal carcinoma, breast cancer, such as breast carcinoma or triple negative breast cancer, kidney cancer, such as kidney renal clear cell carcinoma, ovarian cancer, such as ovarian serous cystadenocarcinoma, glioma, glioblastoma, neuroendocrine tumors, melanoma, small cell lung cancer and sarcoma. In particular, colorectal cancer or small cell lung cancer.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A WRN inhibitor for use as claimed in any of claims 1 to 8, wherein the cancer is selected from MSS (microsatellite stable) MGMT-defective, or MSS (microsatellite stable) MGMT-deficient, or MSS (microsatellite stable) MGMT-silenced, or MGMT-methylated MSS (microsatellite stable) cancer.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A WRN inhibitor for use as claimed in any of claims 1 to 9, wherein the agent i. is administered as:
a pre-treatment agent prior to treatment with the WRN inhibitor,
a combination agent with the WRN inhibitor, without pre-treatment,
both a pre-treatment agent and combination agent with a WRN inhibitor.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A WRN inhibitor for use as claimed in any of claims 1 to 10, wherein the agent i. is temozolomide, and temozolomide is administered:
as a pre-treatment before administration of the WRN inhibitor, or
in combination with the WRN inhibitor, without pre-treatment with temozolomide, or
as a pre-treatment before administration of the WRN inhibitor, followed by combination treatment including temozolomide and the WRN inhibitor,
and the treatment preferably further comprises administration of irinotecan.

### Claim 12

A combination comprising i) a WRN inhibitor and ii) temozolomide, and optionally iii) irinotecan.

### Claim 13 (depends on 12)

A combination according to claim 12, for use in the treatment of cancer, wherein the cancer is MSI-H, dMMR or MSS, in particular MSS.

### Claim 14 (depends on 12, 13)

A combination according to claim 12, for use according to claim 13, wherein the cancer is selected from colorectal cancer (CRC), such as colon adenocarcinoma or rectal adenocarcinoma, gastric cancer, such as stomach adenocarcinoma, prostate cancer, endometrial cancer, adrenocortical cancer, such as adrenocortical carcinoma, cervical cancer, such as cervical squamous cell carcinoma or endocervical adenocarcinoma, uterine cancer, such as uterine corpus endometrial carcinoma and uterine carcinosarcoma, esophageal cancer, such as esophageal carcinoma, breast cancer, such as breast carcinoma or triple negative breast cancer, kidney cancer, such as kidney renal clear cell carcinoma, ovarian cancer, such as ovarian serous cystadenocarcinoma, glioma, glioblastoma, neuroendocrine tumors, melanoma, small cell lung cancer and sarcoma. In particular, colorectal cancer or small cell lung cancer, especially MSS colorectal cancer or MSS small cell lung cancer.

### Claim 15 (depends on 12, 13, 14)

A combination according to claim 12, for use according to claim 13 or 14, wherein the cancer is selected from MSS (microsatellite stable) MGMT-defective, or MSS (microsatellite stable) MGMT-deficient, or MSS (microsatellite stable) MGMT-silenced, or MGMT-methylated MSS (microsatellite stable) cancer.

### Claim 16 (depends on 12, 13, 14, 15)

A combination according to claim 12, for use according to any of claims 13 to 15, wherein the WRN inhibitor is a compound of formula (1g), or a pharmaceutically acceptable salt thereof:
wherein
R1 is selected from:
R15 is H or F;
R16 is H or R25(R24)N—;
R17 is H or F;
R18 is H or F;
R19 is H or F;
R20 is H or F;
R21 is H or CH3;
R22 is H, CF3, CHF2CH2, HOC(O)—CH2—, H3C—C(O)—, (H3C)3C—O—C(O)—;
R23 is H, CF3, CHF2CH2—, (H3C)3C—O—C(O)—;
R24 is CH3;
R25 is CHF2CH2—;
R28 is CH3, H or deuterium;
R27 is H or deuterium;
R2 is the moiety:
wherein R6 is selected from H, Cl, CH3, F, and Br;
R8 is selected from H, Cl, F and CF3;
R9 is selected from H, CH3 and Cl;
R28 is selected from CF3, CF2H, —CH2CH3, Cl, SF5, Br and —C(O)H;
X is selected from C—R7 and N;
R7 is selected from H and F;
R3 is selected from CH3, CH2CH3, cyclopropyl and hydroxyethyl;
R4 is selected from:
wherein
R10 is selected from H, F, Cl, CH3 and OCF3;
R11 is selected from H, Cl, F, and CH3;
R12 is selected from H, Cl and CH3;
R13 is selected from H and CH3;
R14 is selected from H, CH3, —CH2CH3, cyclopropyl, —OCHF2, OCF3 and Cl;
y is 0, 1 or 2;
R5 is CH3; or alternatively, two R5 groups on adjacent carbon atoms join, along with the carbon atoms to which they are attached, to form a fused cyclobutyl ring:
and
* indicates a point of attachment.

### Claim 17 (depends on 12, 13, 14, 15, 16)

A combination according to claim 12 or 16, for use according to any of claims 13 to 15, wherein the WRN inhibitor is Compound A:
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 12, 13, 14, 15, 16, 17)

A combination according to claim 12, 16 or 17, for use according to any of claims 13 to 15, wherein temozolomide is administered:
as a pre-treatment before administration of the WRN inhibitor, or before administration of irinotecan, or before administration of both the WRN inhibitor and irinotecan, without subsequent combination treatment including temozolide, or
in combination, without pre-treatment with temozolomide, or
as a pre-treatment before administration of the WRN inhibitor, or before administration of irinotecan, or before administration of both the WRN inhibitor and irinotecan, followed by combination treatment including temozolomide.

### Claim 19

A method of treating cancer in a subject in need thereof, in particular microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer, the method comprising administering to the subject a therapeutically effective amount of a WRN inhibitor in combination with a therapeutically effective amount of at least one therapeutically active agent selected from the group consisting of a Wee1 inhibitor, an ATR inhibitor, a DNA-PK inhibitor, ionising radiation based therapy selected from i) external beam radiation, ii) brachytherapy and iii) a radiopharmaceutical, a MEK inhibitor, an MDM2 inhibitor, a G4-quadruplex stabilizer, an ATM inhibitor, a CHK1 or CHK2 inhibitor, including dual CHK1 and CHK2 inhibitor, and a DNA polymerase alpha inhibitor.

### Claim 20

A WRN inhibitor for use in the treatment of cancer, in particular microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer, wherein the treatment further comprises administration of at least one therapeutically active agent selected from the group consisting of a Wee1 inhibitor, an ATR inhibitor, a DNA-PK inhibitor, ionising radiation based therapy selected from i) external beam radiation, ii) brachytherapy and iii) a radiopharmaceutical, a MEK inhibitor, an MDM2 inhibitor, a G4-quadruplex stabilizer, an ATM inhibitor, a CHK1 or CHK2 inhibitor, including dual CHK1 and CHK2 inhibitor, and a DNA polymerase alpha inhibitor.

### Claim 21

A combination comprising i) a WRN inhibitor, and ii) at least one therapeutically active agent selected from the group consisting of a Wee1 inhibitor, an ATR inhibitor, a DNA-PK inhibitor, ionising radiation selected from i) external beam radiation, ii) brachytherapy and iii) a radiopharmaceutical, a MEK inhibitor, an MDM2 inhibitor, a G4-quadruplex stabilizer, an ATM inhibitor, a CHK1 or CHK2 inhibitor, including dual CHK1 and CHK2 inhibitor, and a DNA polymerase alpha inhibitor.

### Claim 22

A method of treating cancer in a subject in need thereof, in particular microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer, the method comprising administering to the subject a therapeutically effective amount of a WRN inhibitor in combination with a therapeutically effective amount of at least one chemotherapy agent selected from gemcitabine, camptothecin, irinotecan (Camptosar®), docetaxel (Taxotere®), doxorubicin (e.g. doxorubicin hydrochloride) (Adriamycin®, Rubex®), 5-fluorouracil (Adrucil®, Efudex®), capecitabine (Xeloda®), etoposide (Vepesid®), epirubicin (Ellence®, Pharmorubicin®), oxaliplatin (Eloxatin®), mitomycin (e.g. mitomycin A, mitomycin B or mitomycin C, particularly mitomycin C), cisplatin (Platinol®), carboplatin (Paraplatin®), bleomycin and paclitaxel (Taxol®). In particular, the chemotherapy agent is selected from irinotecan (Camptosar®), 5-fluorouracil (Adrucil®, Efudex®), epirubicin (Ellence®, Pharmorubicin®), doxorubicin (e.g. doxorubicin hydrochloride) (Adriamycin®, Rubex®), gemcitabine, camptothecin and mitomycin C.

### Claim 23 (depends on 19, 20, 22)

The method according to claim 19 or 22, or the WRN inhibitor for use according to claim 20, wherein the cancer is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).

### Claim 24 (depends on 19, 20, 21, 22, 23)

The method according to any of claim 19, 22, or 23, or the WRN inhibitor for use according to claim 20 or 23, or the combination according to claim 21, wherein the (at least one) therapeutically active agent is a WEE1 inhibitor, and the WEE1 inhibitor is adavosertib (also known as AZD1775 and MK-1775).

### Claim 25 (depends on 19, 20, 21, 22, 23)

The method according to any of claim 19, 22, or 23, or the WRN inhibitor for use according to claim 20 or 23, or the combination according to claim 21, wherein the (at least one) therapeutically active agent is the ATR inhibitor elimusertib (also known as BAY-1895344).

### Claim 26 (depends on 19, 20, 21, 22, 23)

The method according to any of claim 19, 22, or 23, or the WRN inhibitor for use according to claim 20 or 23, or the combination according to claim 21, wherein the (at least one) therapeutically active agent is the DNA-PK inhibitor AZD7648 or NU7441.

### Claim 27 (depends on 19, 20, 21, 22, 23)

The method according to any of claim 19, 22, or 23, or the WRN inhibitor for use according to claim 20 or 23, or the combination according to claim 21, wherein the (at least one) therapeutically active agent is an ionising radiation based therapy selected from i) external beam radiation, ii) brachytherapy and iii) a radiopharmaceutical.

### Claim 28 (depends on 19, 20, 21, 22, 23)

The method according to any of claim 19, 22, or 23, or the WRN inhibitor for use according to claim 20 or 23, or the combination according to claim 21, wherein the ionising radiation is external beam radiation.

### Claim 29 (depends on 19, 20, 21, 22, 23)

The method according to any of claim 19, 22, or 23, or the WRN inhibitor for use according to claim 20 or 23, or the combination according to claim 21, wherein the (at least one) therapeutically active agent is the MEK inhibitor trametinib.

### Claim 30 (depends on 19, 20, 21, 22, 23)

The method according to any of claim 19, 22, or 23, or the WRN inhibitor for use according to claim 20 or 23, or the combination according to claim 21, wherein the (at least one) therapeutically active agent is the MDM2 inhibitor HDM201 (also known as siremadlin), or a pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 19, 20, 21, 22, 23)

The method according to any of claim 19, 22, or 23, or the WRN inhibitor for use according to claim 20 or 23, or the combination according to claim 21, wherein the (at least one) therapeutically active agent is the G4-quadruplex stabilizer pyridostatin.

### Claim 32 (depends on 19, 20, 21, 22, 23)

The method according to any of claim 19, 22, or 23, or the WRN inhibitor for use according to claim 20 or 23, or the combination according to claim 21, wherein the (at least one) therapeutically active agent is the ATM inhibitor KU-60019.

### Claim 33 (depends on 19, 20, 21, 22, 23)

The method according to any of claim 19, 22, or 23, or the WRN inhibitor for use according to claim 20 or 23, or the combination according to claim 21, wherein the (at least one) therapeutically active agent is the dual CHK1 and CHK2 inhibitor AZD7762.

### Claim 34 (depends on 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method according to any of claim 19 or 22 to 33, or the WRN inhibitor for use according to claim 20 or 23 to 33, wherein the cancer is selected from colorectal cancer (CRC), such as colon adenocarcinoma or rectal adenocarcinoma, gastric cancer, such as stomach adenocarcinoma, prostate cancer, endometrial cancer, adrenocortical cancer, such as adrenocortical carcinoma, cervical cancer, such as cervical squamous cell carcinoma or endocervical adenocarcinoma, uterine cancer, such as uterine corpus endometrial carcinoma and uterine carcinosarcoma, esophageal cancer, such as esophageal carcinoma, breast cancer, such as breast carcinoma or triple negative breast cancer, kidney cancer, such as kidney renal clear cell carcinoma, ovarian cancer, such as ovarian serous cystadenocarcinoma, glioma, glioblastoma, neuroendocrine tumors, melanoma, small cell lung cancer and sarcoma.

### Claim 35 (depends on 34)

The method according to claim 34, or the WRN inhibitor for use according to claim 34, wherein the cancer is colorectal cancer (CRC) or gastric cancer, particularly colorectal cancer (CRC).

### Claim 36

A method of treating colorectal cancer, in particular microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer, the method comprising administering to a subject a therapeutically effective amount of a WRN inhibitor in combination with a therapeutically effective amount of a topoisomerase inhibitor.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the topoisomerase inhibitor is QAP1, etoposide, irinotecan or camptothecin.

### Claim 38 (depends on 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method according to any of claim 19 or 22 to 35, or the method according to claim 36 or 37, or the WRN inhibitor for use according to claim 20 or 23 to 35, wherein the WRN inhibitor is a compound of formula (1g), or a pharmaceutically acceptable salt thereof:
wherein
R1 is selected from:
R15 is H or F;
R16 is H or R25(R24)N—;
R17 is H or F;
R18 is H or F;
R19 is H or F;
R20 is H or F;
R21 is H or CH3;
R22 is H, CF3, CHF2CH2, HOC(O)—CH2—, H3C—C(O)—, (H3C)3C—O—C(O)—;
R23 is H, CF3, CHF2CH2—, (H3C)3C—O—C(O)—;
R24 is CH3;
R25 is CHF2CH2—;
R28 is CH3, H or deuterium;
R27 is H or deuterium;
R2 is the moiety:
wherein R6 is selected from H, Cl, CH3, F, and Br;
R8 is selected from H, Cl, F and CF3;
R9 is selected from H, CH3 and Cl;
R28 is selected from CF3, CF2H, —CH2CH3, Cl, SF5, Br and —C(O)H;
X is selected from C—R7 and N;
R7 is selected from H and F;
R3 is selected from CH3, CH2CH3, cyclopropyl and hydroxyethyl;
R4 is selected from:
wherein
R10 is selected from H, F, Cl, CH3 and OCF3;
R11 is selected from H, Cl, F, and CH3;
R12 is selected from H, Cl and CH3;
R13 is selected from H and CH3;
R14 is selected from H, CH3, —CH2CH3, cyclopropyl, —OCHF2, OCF3 and Cl;
y is 0, 1 or 2;
R5 is CH3; or alternatively, two R5 groups on adjacent carbon atoms join, along with the carbon atoms to which they are attached, to form a fused cyclobutyl ring:
and
* indicates a point of attachment.

### Claim 39 (depends on 21, 38)

The method according to claim 38, the WRN inhibitor for use according to claim 38, or the combination according to claim 21, wherein the WRN inhibitor is:
or a pharmaceutically acceptable salt thereof.
